The funding comes from UK-based investor JuvVentures. The company says it is leveraging its own drug-delivery technology to make an existing Parkinson’s medication, apomorphine, more effective ...

Opens in a new tab or window The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced Parkinson's disease, Supernus ...

According to DelveInsight’s epidemiology model, the total diagnosed prevalent cases of Parkinson’s disease were approximately 1,210 thousand in the US in 2023 which is expected to increase during the ...

as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). Supernus will make ONAPGO available in ...

The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...

Onapgo is the first subcutaneous apomorphine infusion device approved to treat motor fluctuations in Parkinson’s disease. Onapgo reduced “off” time, as well as increased “good on” time ...

Feb. 6. 2025 – The FDA has approved a new wearable device for adults with advanced Parkinson’s disease. Sold as Onapgo, this device gives a steady dose of apomorphine – a medicine that ...

The U.S. pharma Sunovion has said its under-the-tongue film for Parkinson's has hit target in a late ... trial evaluated Sunovion’s sublingual apomorphine in patients with PD who experience ...

But Parkinson’s patients also experience “off” times when levodopa therapy wears off and motor symptoms return. One treatment option for these off periods is a different drug, apomorphine.